Company Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs.
The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF.
The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Feb 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 93 |
| CEO | Raymond Stevens |
Contact Details
Address: 601 Gateway Boulevard, Suite 900 South San Francisco, California 94080 United States | |
| Phone | 650 457 1978 |
| Website | structuretx.com |
Stock Details
| Ticker Symbol | GPCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001888886 |
| CUSIP Number | 86366E106 |
| ISIN Number | US86366E1064 |
| Employer ID | 98-1480821 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raymond C. Stevens Ph.D. | Chief Executive Officer and Director |
| Jun S. Yoon | Co- Founder, Chief Financial Officer and Secretary |
| Dr. Yingli Ma Ph.D. | Chief Technology Officer |
| Dr. Xichen Lin Ph.D. | Chief Scientific Officer |
| Tony Peng | Senior Vice President of Legal |
| Bob Gatmaitan | Senior Vice President of People |
| Dr. Hui Lei Ph.D. | Senior Vice President of Chemistry |
| Dr. Fang Zhang Ph.D. | Executive Vice President and Head of Biology |
| Lani Ibarra | Senior Vice President of Clinical Development Operations |
| Dr. Xinglong Jiang Ph.D. | Senior Vice President of Preclinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 17, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 17, 2024 | 8-K | Current Report |